DPP4 and myeloid sarcoma: In this study, we reported for the first time that SIT, as the first approved DPP4 inhibitor by the FDA to treat T2DM and MS, attenuated HFD/PA-induced ED and endothelial injuries in the thoracic aorta and HUVECs.